Protagonist Therapeutics (NASDAQ: PTGX) CFO sells shares to cover RSU taxes

Rhea-AI Filing Summary

Protagonist Therapeutics Chief Financial Officer Ali Asif reported an open-market sale of 1,750 shares of common stock at $105.47 per share on April 20, 2026. According to the filing, the sale was made to cover tax withholding obligations triggered by the settlement of restricted stock units.

After this transaction, Asif directly holds 59,003 shares of Protagonist Therapeutics common stock, indicating that the sale represents a small portion of his overall reported holdings.

Insider Trade Summary

Net Seller: 1,750 shares ($184,573)

Net Sell 1 txn

Insider Ali Asif

Role Chief Financial Officer

Sold 1,750 shs ($185K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,750	$105.47	$185K

Holdings After Transaction: Common Stock — 59,003 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 1,750 shares Sale price: $105.47 per share Shares held after: 59,003 shares

3 metrics

Shares sold 1,750 shares Open-market sale on April 20, 2026

Sale price $105.47 per share Price for common stock sold

Shares held after 59,003 shares Direct common stock holdings after transaction

Key Terms

restricted stock units, tax withholding obligation, open-market sale

3 terms

restricted stock units financial

"tax withholding obligation incurred upon settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligation financial

"Sale of shares to cover tax withholding obligation incurred"

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ali Asif

(Last) (First) (Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK CALIFORNIA 94560-1160

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		S		1,750(1)	D	$105.47	59,003	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units.

	/s/ Matthew Gosling, Attorney-in-Fact for Asif Ali	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PTGX CFO Ali Asif report?

Ali Asif reported selling 1,750 shares of Protagonist Therapeutics common stock. The shares were sold at $105.47 per share to cover tax withholding obligations arising from restricted stock unit settlement, rather than as a discretionary open-market reduction of his overall equity position.

How many PTGX shares did the CFO sell and at what price?

The CFO sold 1,750 shares of Protagonist Therapeutics common stock at $105.47 per share. This transaction is described as an open-market sale specifically to satisfy tax withholding obligations tied to the settlement of restricted stock units granted as compensation.

Why did the Protagonist Therapeutics CFO sell PTGX shares?

The sale was undertaken to cover tax withholding obligations incurred when restricted stock units settled. Instead of paying taxes in cash, a portion of shares was sold, a common practice for equity compensation, and does not necessarily reflect a change in the executive’s long-term view of the company.

How many PTGX shares does the CFO hold after this transaction?

Following the reported sale, the CFO holds 59,003 shares of Protagonist Therapeutics common stock directly. This remaining balance suggests the 1,750 shares sold for tax withholding represent a relatively small fraction of his overall reported equity stake in the company.

Was the PTGX CFO’s share sale part of routine compensation-related activity?

Yes. The filing states the sale covered tax withholding obligations from restricted stock unit settlement. Such transactions typically occur automatically when equity awards vest, converting part of the award into cash for taxes while leaving the executive with the remaining net shares.